 - To evaluate the efficacy of vismodegib in patients with relapsedrefractory B-cell lymphoma and CLL by measuring the overall OR and complete response CR rate during the study period, the maximum tumor shrinkage, the duration of response, the progression-free survival PFS and the overall survival OS. 